When was Excellergy founded?

Excellergy was founded in 2020 and raised its 1st funding round 5 years after it was founded.

Where is Excellergy located?

Excellergy is headquartered in Palo Alto, United States.

How many employees does Excellergy have?

As of May 31, 2026, the latest employee count at Excellergy is 14.

Is Excellergy a funded company?

Excellergy is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Oct 13, 2025.

When was the latest funding round of Excellergy?

Excellergy's latest funding was a $***** Series A round on Oct 13, 2025, with participation from 3 investors. Its primary sector is Immunology. In United States, the Immunology sector has seen $4.23B in funding in 2026 to date.

Where does Excellergy rank among its competitors?

Excellergy ranks 17th amongst 64 active competitors, of which 21 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Excellergy, which secured $70M in Oct, 2025.

Who are the top competitors of Excellergy?

Excellergy's top competitors include Stallergenes Greer, Immunomic Therapeutics and Mabylon. Among them, Excellergy secured the most recent funding round in October, 2025.

Excellergy - 2026 Company Profile, Team, Funding & Competitors

Q: Is Excellergy an acquired company?

Excellergy got acquired by Novartis on Mar 27, 2026.

Company Details

Developer of trifunctional effector cell response inhibitors for allergic diseases. It focuses on advancing beyond traditional anti-IgE approaches. The company targets IgE bound to the effector cell, the source of allergic signaling. It aims to improve patient quality of life by combating severe allergic diseases.

Website: excellergy.com
Email ID: *****@excellergy.com
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

Palo Alto, United States

Stage

Acquired

Total Funding

$70M in 1 round

Latest Funding Round

Series A, Oct 13, 2025, $*****

Investors

Samsara BioCapital & 2 more

Ranked

17^th among 64 active competitors

Employee Count

14 as on May 31, 2026

Similar Companies

Stallergenes Greer & 74 more

Exit Details

Acquired by Novartis (Mar 27, 2026)

View Excellergy's full profile

Excellergy got acquired by Novartis on Mar 27, 2026 at an acquisition amount of $*****.

Click here to take a look at Excellergy's acquisition in detail

Excellergy has raised a total funding of $70M over 1 round. Its latest funding round was a Series A round on Oct 13, 2025 for $*****. 3 investors participated in its latest round. Excellergy has 3 institutional investors.

Here is the list of recent funding rounds of Excellergy:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 13, 2025	1174959	Series A	2960912	5100739	4630805	7913973

Access funding benchmarks and valuations. Sign up today!

View details of Excellergy's funding rounds and investors

The founders of Excellergy are Alexander Eggel, Theodore Jardetzky and Geoff Harris. Todd Zavodnick is the CEO of Excellergy.

Here are the details of Excellergy's key team members:

Alexander Eggel: Co-Founder of Excellergy and founder of 1 other company.
Theodore Jardetzky: Co-Founder of Excellergy.
Geoff Harris: Co-Founder & Chief Scientific Officer of Excellergy.
Todd Zavodnick: CEO of Excellergy.
Contact Info: 1 email address

View details of Excellergy's Founder profiles and Board Members

Excellergy's employee count trend

Excellergy has 14 employees as of May 26. Here is Excellergy's employee count trend over the years:

Uncover Excellergy's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Excellergy include Stallergenes Greer, Immunomic Therapeutics and Mabylon. Here is the list of Top 10 competitors of Excellergy, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Stallergenes Greer 2013, London (United Kingdom), Acquired	Developing allergen immunotherapy (vaccine) for respiratory allergies	-	Waypoint Capital, B-FLEXION	62/100
2nd	Immunomic Therapeutics 2005, Rockville (United States), Series B	Vaccines for allergy, cancer and infectious disease.	$104M	HLB, Defense.gov & 7 others	62/100
3rd	Mabylon 2015, Schlieren (Switzerland), Series B	Developer of therapeutics for allergies and neurodegenerative diseases	$37M	Admin, EIC Fund & 3 others	60/100
4th	RAPT 2015, San Francisco (United States), Acquired	Provider of immunology-based drug for oncology and inflammatory diseases	$199M	The Column Group, Celgene & 19 others	59/100
5th	Desentum 2011, Espoo (Finland), Series C	Developing novel types of allergen immunotherapy products (allergy vaccines)	$26.7M	Springvest, Cascara Ventures & 4 others	55/100
6th	Aravax 2015, Melbourne (Australia), Series B	Developer of vaccine for peanut allergy	$49M	Tenmile, Medical Research Commercialisation Fund ... & 6 others	55/100
7th	Allergy Therapeutics 1998, Worthing (United Kingdom), Public	Developer of treatments for allergy and immune related disorders	-	Eiffel Investment Group	52/100
8th	ALK-Abello 1923, Horsholm (Denmark), Public	Danish, Public Biopharma company developing allergy immunotherapies including injections (emergency) and sublingual tablets.	-	Merck	52/100
9th	IgGenix 2019, San Francisco (United States), Series B	Developer of therapeutic solutions for treating food allergy	$75M	Khosla Ventures, Alexandria & 7 others	51/100
10th	Moonlight Therapeutics 2017, Atlanta (United States), Seed	Developer of therapies for people suffering from food allergies	$2.42M	seedToB, NIAID & 3 others	51/100
17th	Excellergy 2020, Palo Alto (United States), Acquired	Developer of trifunctional effector cell response inhibitors for allergic diseases	$70M	Decheng Capital, Samsara BioCapital & 1 others	42/100